---
title: "IKT.US (IKT.US) — 相關新聞"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/IKT.US/news.md"
symbol: "IKT.US"
name: "IKT.US"
parent: "https://longbridge.com/zh-HK/quote/IKT.US.md"
datetime: "2026-03-15T23:29:56.003Z"
locales:
  - [en](https://longbridge.com/en/quote/IKT.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/IKT.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/IKT.US/news.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/IKT.US/news.md) | [简体中文](https://longbridge.com/zh-CN/quote/IKT.US/news.md)


# IKT.US (IKT.US) — 相關新聞

### [Inhibitor Therapeutics Announces $3 Million Equity Financing](https://longbridge.com/zh-HK/news/276747735.md)
*2026-02-24T14:07:04.000Z*
> Inhibitor Therapeutics, Inc. has announced a $3 million equity financing through a securities purchase agreement with an

### [Bank of America Predicts Up to 240% Jump for These 2 'Strong Buy' Stocks](https://longbridge.com/zh-HK/news/276511767.md)
*2026-02-21T11:15:00.000Z*
> Bank of America analysts predict significant gains for two biotech stocks, with potential upside of up to 240%. The biot

### [Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of "Buy" from Analysts](https://longbridge.com/zh-HK/news/276000681.md)
*2026-02-15T09:14:47.000Z*
> Inhibikase Therapeutics, Inc. (NASDAQ:IKT) has received a consensus rating of "Buy" from five research firms. Among the 

### [Inhibikase Therapeutics (NASDAQ:IKT) Trading Up 6.9%  - Time to Buy?](https://longbridge.com/zh-HK/news/275743895.md)
*2026-02-12T11:02:14.000Z*
> Inhibikase Therapeutics (NASDAQ:IKT) shares rose 6.9% to $1.71 during mid-day trading. The stock's trading volume decrea

### [Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to Sell at Wall Street Zen](https://longbridge.com/zh-HK/news/270886211.md)
*2025-12-27T06:49:54.000Z*
> Wall Street Zen upgraded Inhibikase Therapeutics (NASDAQ:IKT) to a "sell" rating. Other analysts have given mixed rating

### [Inhibikase Therapeutics: Late-Stage IKT-001 PAH Program and De-Risked 505(b)(2) Pathway Support Buy Rating and $8 Target](https://longbridge.com/zh-HK/news/270845959.md)
*2025-12-26T11:15:15.000Z*
> Ram Selvaraju from H.C. Wainwright has initiated a Buy rating on Inhibikase Therapeutics (IKT) with an $8 target, citing

### [While institutions invested in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) benefited from last week's 11% gain, individual investors stood to gain the most](https://longbridge.com/zh-HK/news/269875079.md)
*2025-12-16T13:50:43.000Z*
> Inhibikase Therapeutics (NASDAQ:IKT) saw an 11% stock price increase last week, benefiting individual investors the most

### [FY2025 Earnings Estimate for IKT Issued By Lifesci Capital](https://longbridge.com/zh-HK/news/268623509.md)
*2025-12-04T13:38:11.000Z*
> Lifesci Capital issued FY2025 EPS estimates for Inhibikase Therapeutics, predicting earnings of ($0.57) per share. The c